Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 January 2018 Photo Charl Devenish
Researcher tackling drug-resistant TB through molecular methods
Dr Anneke van der Spoel van Dijk is invested in contributing to the global effort of stopping TB by 2035.

The work of Dr Anneke van der Spoel van Dijk investigates the spread of TB in the Free State population using techniques such as next generation sequencing, spoligotyping and MIRU-VNTR typing. Dr Van der Spoel van Dijk, a senior medical scientist in the Department of Medical Microbiology at the University of the Free State (UFS) also looks at drug resistance in her research. This work informs decisions about how best to treat patients with multidrug-resistant TB (MDR-TB). 

She employs rapid molecular techniques to track one of Africa’s most serious diseases, tuberculosis (TB). 

Drug resistance
Scientists assist the National Health Laboratory Service and Department of Health in trying to refine the diagnostic tools to identify these cases earlier. Dr Van der Spoel van Dijk explains: “Until recently, it took up to two years to fine-tune treatment decisions for patients with MDR-TB. Patients get a cocktail of anti-TB drugs, but it takes time to find the right combination. Re-infection and relapse (patients stopping treatment for several reasons) add to the diagnostic and treatment management challenges.

Enormous impact
“Now doctors can reduce the time needed for diagnostic certainty to about seven days, while new drugs allow reduction of treatment from more than 18 to nine months. This can have an enormous impact on the life of many patients.”

Dr Van der Spoel van Dijk’s work forms part of research in the faculty looking at resistance development in TB strains. She is currently also doing her doctoral thesis on the differences and incidence of MDR-TB among adolescents versus adults. Dr Van der Spoel van Dijk says: “It is a complicated picture, but we hope to unravel it to support better diagnostic tools and patient care.”

As part of the National Health Laboratory Service, her department is playing an important role in TB diagnostics and the training of scientists and future pathologists. “Our work is contributing to the global vision to stop TB by 2035,” Dr Van der Spoel van Dijk says.

News Archive

UFS shares expertise in Sign Language
2009-05-07

 
The University of the Free State (UFS) is continuing in its commitment to reach out to other universities on the African continent. Mr Philemon Akach (pictured), a senior lecturer in the Department of Afro-Asiatic Studies, Sign Language and Language Practice, recently visited the University of Ghana to share his expertise and assist in the introduction of the Ghanaian Sign Language (GSL) as an academic course in that institution. The course will first be piloted as an “elective course” and if successful it will be a permanent feature of the University of Ghana's calendar.

Mr Akach has been instrumental in the development of GSL since the United Nations Educational, Scientific and Cultural Organization (UNESCO) sent him on a fact-finding mission regarding the education of deaf children in Ghana in 1993. Since then he has trained interpreters as well as parents and teachers of deaf children in Ghana in using the South African Sign Language multimedia grammar teaching materials. He has also guided the GSL Dictionary Project. The University of Ghana will use his books as the basis for the teaching of the GSL. This session was a follow-up to the one he had with that university in February this year.

The UFS is widely regarded as a beacon of light in the teaching of sign language on the continent and, together with the University of Witwatersrand, are the only universities in South Africa that offer sign language as an academic course.
Photo: Mangaliso Radebe

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept